Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 4/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.54 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.50 |
| ▸ | CDK9 | P50750 | 2/20 | 0.50 |
| ▸ | PTPRF | P10586 | 2/20 | 0.49 |
| ▸ | CDC25B | P30305 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9572014 | 0.88 | PTPRC (0.78) | PTPRCCDK2CCNE2CDK4CCND1 | |
| SCHEMBL31194258 | 0.88 | PTPRC (0.78) | PTPRCCDK2CCNE2CDK4CCND1 | |
| SCHEMBL9572025 | 0.85 | PTPRC (0.74) | PTPRCCDK2CCNE2CDK4CCND1 | |
| SCHEMBL9572018 | 0.77 | PTPRC (0.62) | PTPRCCDK2CCNE2CDK4CCND1 | |
| SCHEMBL7716530 | 0.77 | PTPRC (0.62) | PTPRCCDK2CCNE2CDK4CCND1 | |
| SCHEMBL10791127 | 0.77 | PTPRC (0.62) | PTPRCCDK2CCNE2CDK4CCND1 | |
| SCHEMBL9572021 | 0.75 | PTPRC (0.60) | PTPRCCDK2CCNE2CDK4CCND1 | |
| SCHEMBL10436037 | 0.75 | PTPRC (0.60) | PTPRCCDK2CCNE2CDK4CCND1 | |
| SCHEMBL28505491 | 0.74 | CDK2 (0.60) | PTPRCCDK2CCNE2CDK4CCND1 | |
| SCHEMBL27616714 | 0.74 | PTPRC (0.58) | PTPRCCDK2CCNE2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0560682-B1 | Keratinous fibres dye compositions with 4-monoindolyl 1,2-naphthochinones, 4-monoindolyl 1,2-naphthoquinones | OREAL (FR) | 1996-08-07 | — | — | EP | claimed |
| EP-0560682-A1 | Keratinous fibres dye compositions with 4-monoindolyl 1,2-naphthochinones, 4-monoindolyl 1,2-naphthoquinones | L'OREAL (FR) | 1993-09-15 | — | — | EP | claimed |
| US-6939896-B2 | Naphthalenedione derivatives; treating autoimmune diseases and organ graft rejection | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| EP-1259231-B1 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| US-20030119897-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | disclosed |
| EP-1259231-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001045681-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| EP-0560682-B1 | Keratinous fibres dye compositions with 4-monoindolyl 1,2-naphthochinones, 4-monoindolyl 1,2-naphthoquinones | OREAL (FR) | 1996-08-07 | — | — | EP | disclosed |
| EP-0560682-A1 | Keratinous fibres dye compositions with 4-monoindolyl 1,2-naphthochinones, 4-monoindolyl 1,2-naphthoquinones | L'OREAL (FR) | 1993-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119897-A1 | Cd45 inhibitors | PTPRC, CD2, HLA-C | PTPRC 1/4885PTPN1 18/4885CDK2 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.